We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$588M
1-Year Est. Return
182.75%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$233M
AUM Growth
–
Cap. Flow
+$273M
Cap. Flow
% of AUM
117.2%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
107
New
107
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$9.19M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$8.94M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$6.13M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$5.88M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$5.46M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Keros Therapeutics
KROS
$199M
| $1.01M | 0.43% |
+63,547
| New | +$3.3M |
|
52
BioNTech
BNTX
$22.9B
| $999K | 0.43% |
+8,767
| New | +$1M |
|
53
Viridian Therapeutics
VRDN
$2.09B
| $948K | 0.41% |
+49,478
| New | +$1.08M |
|
|
FOLD
54
CALL
DELISTED
Amicus Therapeutics
FOLD
| $942K | 0.4% |
+100,000
| New | +$1.04M |
|
55
PUT
Janux Therapeutics
JANX
$925M
| $937K | 0.4% |
+17,500
| New | +$926K |
|
56
CALL
Ocular Therapeutix
OCUL
$1.79B
| $888K | 0.38% |
+104,000
| New | +$1.01M |
|
|
FLNA
57
PUT
Filana Therapeutics
FLNA
$48.8M
| $876K | 0.38% |
+371,300
| New | +$6.52M |
|
58
CALL
Neumora Therapeutics
NMRA
$298M
| $861K | 0.37% |
+81,200
| New | +$973K |
|
59
Vaxcyte
PCVX
$7.81B
| $819K | 0.35% |
+10,000
| New | +$993K |
|
60
PUT
Capricor Therapeutics
CAPR
$223M
| $810K | 0.35% |
+58,700
| New | +$1.03M |
|
|
61
PUT
Keros Therapeutics
KROS
$199M
| $798K | 0.34% |
+50,400
| New | +$2.62M |
|
|
ACLX
62
DELISTED
Arcellx
ACLX
| $775K | 0.33% |
+10,100
| New | +$873K |
|
63
CALL
Iovance Biotherapeutics
IOVA
$1.82B
| $740K | 0.32% |
+100,000
| New | +$927K |
|
64
CALL
Vir Biotechnology
VIR
$1.46B
| $734K | 0.31% |
+100,000
| New | +$789K |
|
65
GH Research
GHRS
$1.93B
| $711K | 0.3% |
+101,502
| New | +$816K |
|
66
Geron
GERN
$828M
| $708K | 0.3% |
+200,000
| New | +$799K |
|
67
Cogent Biosciences
COGT
$6.65B
| $702K | 0.3% |
+90,000
| New | +$897K |
|
|
CLYM
68
Climb Bio
CLYM
$681M
| $674K | 0.29% |
+374,423
| New | +$1.35M |
|
69
Nektar Therapeutics
NKTR
$2.39B
| $650K | 0.28% |
+46,595
| New | +$822K |
|
70
UroGen Pharma
URGN
$1.86B
| $533K | 0.23% |
+50,000
| New | +$599K |
|
|
JBIO
71
PUT
Jade Biosciences
JBIO
$1.2B
| $508K | 0.22% |
+5,474
| New | +$472K |
|
72
Alector
ALEC
$168M
| $452K | 0.19% |
+239,019
| New | +$900K |
|
73
argenx
ARGX
$53.4B
| $422K | 0.18% |
+679
| New | +$398K |
|
|
ONC
74
BeOne Medicines Ltd
ONC
$32.8B
| $422K | 0.18% |
+30,000
| New | +$6.13M |
|
75
ProQR Therapeutics
PRQR
$243M
| $419K | 0.18% |
+158,023
| New | +$502K |
|
Similar funds
MC
PFG
FMI
EGWAG
PFG
GIM
FL
BA
Diadema Partners's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Diadema Partners, which disclosed 107 positions worth $233M. Its ten largest holdings account for 44% of the portfolio.
Its largest position is AbbVie: 50,000 shares worth $8.88M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets.
- Diadema Partners's largest Q4 2024 buy was AbbVie: 50,000 shares worth $8.88M.
- Diadema Partners's ten largest holdings make up 44% of its $233M portfolio in Q4 2024.
- Diadema Partners disclosed 107 positions in Q4 2024, its first 13F filing on record.
Based on Diadema Partners's 13F filing for Q4 2024, filed 14 Feb 2025.